Predictive factors of efficacy of combination therapy with basal insulin and liraglutide in type 2 diabetes when switched from longstanding basal-bolus insulin: Association between the responses of β- and α-cells to GLP-1 stimulation and the glycaemic control at 6 months after switching therapy.

Horie I, Haraguchi A, Sako A, Akeshima J, Niri T, Shigeno R, Ito A, Nozaki A, Natsuda S, Akazawa S, Mori Y, Ando T, Kawakami A, Abiru N

Diabetes research and clinical practice6 Sept 2018Cited by 5 (Europe PMC)

PMID30194951DOI10.1016/j.diabres.2018.08.015PepBankPUB-30194951

Source link PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. 4 results from people.

01HumanNon-randomized trialMechanism
In patients with type 2 diabetes, paradoxical hyperglucagonemia during an oral glucose tolerance test improved significantly after liraglutide administration in both good- and poor-responders.
In plain wordsIn adults with type 2 diabetes, an abnormal rise of glucagon after a sugar drink improved after liraglutide in both groups.
Peptide
Liraglutide
Outcome
DecreaseParadoxical hyperglucagonemia during OGTT after liraglutide
Study
n = 41
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
Dose not stated · 2 daysAs given in this study (human).
Source sentences
Summary
2nd-OGTT revealed that paradoxical hyperglucagonemia were significantly improved in both groups
2 context sentences(design, population, supporting numbers)
Summary · context
We studied 41 patients who switched from basal-bolus insulin therapy of more than 3 years to basal insulin/liraglutide combination therapy.
Summary · context
To evaluate the glucose-dependent insulin/glucagon responses without/with liraglutide, a 75-g oral glucose tolerance test (OGTT) was performed twice, before (1st-OGTT) and 2-days after (2nd-OGTT) liraglutide administration.
Report a problemFND-3019495102
02HumanNon-randomized trialMechanism
In patients with type 2 diabetes, a larger improvement in insulin response from the first to the second OGTT, with liraglutide, was associated with being a good-responder.
In plain wordsIn adults with type 2 diabetes, a stronger insulin response after liraglutide was linked to a better blood sugar result later.
Peptide
Liraglutide
Outcome
Not applicableAssociation of insulin-response improvement with good response
Study
n = 41
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
Dose not stated · 2 daysAs given in this study (human).
Source sentences
Summary
Logistic regression analyses revealed that the improvement of the insulin-response during 2nd-OGTT compared to that during 1st-OGTT is associated with the good-responder.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied 41 patients who switched from basal-bolus insulin therapy of more than 3 years to basal insulin/liraglutide combination therapy.
Summary · context
To evaluate the glucose-dependent insulin/glucagon responses without/with liraglutide, a 75-g oral glucose tolerance test (OGTT) was performed twice, before (1st-OGTT) and 2-days after (2nd-OGTT) liraglutide administration.
Report a problemFND-3019495105
03HumanNon-randomized trialMechanism
In good-responders with type 2 diabetes, insulin secretory response during an oral glucose tolerance test increased significantly after liraglutide administration.
In plain wordsIn adults with type 2 diabetes who responded well, insulin release after a sugar drink rose after liraglutide.
Peptide
Liraglutide
Outcome
IncreaseInsulin secretory response during OGTT in good-responders
Study
n = 28
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
Dose not stated · 2 daysAs given in this study (human).
Source sentences
Summary
but significant increases in insulin secretory response were observed only in good-responders.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied 41 patients who switched from basal-bolus insulin therapy of more than 3 years to basal insulin/liraglutide combination therapy.
Summary · context
To evaluate the glucose-dependent insulin/glucagon responses without/with liraglutide, a 75-g oral glucose tolerance test (OGTT) was performed twice, before (1st-OGTT) and 2-days after (2nd-OGTT) liraglutide administration.
Report a problemFND-3019495103
04HumanNon-randomized trialMechanism
In poor-responders with type 2 diabetes, insulin secretory response during an oral glucose tolerance test did not increase significantly after liraglutide administration.
In plain wordsIn adults with type 2 diabetes who responded poorly, insulin release after a sugar drink did not clearly rise after liraglutide.
Peptide
Liraglutide
Outcome
No significant changeInsulin secretory response during OGTT in poor-responders
Study
n: not reported in source
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
Dose not stated · 2 daysAs given in this study (human).
Source sentences
Summary
but significant increases in insulin secretory response were observed only in good-responders.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied 41 patients who switched from basal-bolus insulin therapy of more than 3 years to basal insulin/liraglutide combination therapy.
Summary · context
To evaluate the glucose-dependent insulin/glucagon responses without/with liraglutide, a 75-g oral glucose tolerance test (OGTT) was performed twice, before (1st-OGTT) and 2-days after (2nd-OGTT) liraglutide administration.
Report a problemFND-3019495104

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

05HumanNot a test of Liraglutide aloneNon-randomized trialEfficacy outcome
In patients with type 2 diabetes switched from basal-bolus insulin, 68.3% of 41 were good responders at 6 months to the combination of basal insulin and liraglutide.
In plain wordsIn adults with type 2 diabetes, about two thirds responded well to a switch to basal insulin plus liraglutide.
Peptide
Liraglutide
Outcome
Not applicableGood glycaemic response at 6 months with basal insulin plus liraglutide
Study
n = 41
Outcome group
Glycemic control · Metabolic and weight
Measurements
Good-responders
68.3%
basal insulin plus liraglutide
Source sentences
Summary
Twenty-eight patients (68.3%) were identified as good-responders.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied 41 patients who switched from basal-bolus insulin therapy of more than 3 years to basal insulin/liraglutide combination therapy.
Summary · context
To evaluate the glucose-dependent insulin/glucagon responses without/with liraglutide, a 75-g oral glucose tolerance test (OGTT) was performed twice, before (1st-OGTT) and 2-days after (2nd-OGTT) liraglutide administration.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3019495101

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.